Beam Therapeutics (BEAM) Current Assets (2019 - 2026)

Beam Therapeutics (BEAM) has 8 years of Current Assets data on file, last reported at $1.3 billion in Q1 2026.

• Current Assets for Q1 2026 came in at $1.3 billion, up 1.55% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.3 billion (up 1.55% YoY), and the FY2025 annual result was $1.3 billion, up 44.47% from the prior year.
• Current Assets steadied at $1.3 billion in Q1 2026 per BEAM's latest filing, from $1.3 billion in the prior quarter.
• Over five years, Current Assets peaked at $1.3 billion in Q4 2025 and troughed at $878.1 million in Q4 2024.
• A 5-year average of $1.1 billion and a median of $1.1 billion in 2022 frame the typical range for Current Assets.
• The sharpest annual moves came in 2022 and 2024: Current Assets surged 140.87% in 2022, then fell 27.49% in 2024.
• A 5-year view of Current Assets shows it stood at $1.1 billion in 2022, then grew by 10.81% to $1.2 billion in 2023, then slipped by 27.49% to $878.1 million in 2024, then jumped by 44.47% to $1.3 billion in 2025, then declined by 0.14% to $1.3 billion in 2026.
• Business Quant data shows BEAM's Current Assets at $1.3 billion in Q1 2026, $1.3 billion in Q4 2025, and $1.1 billion in Q3 2025.